Conserved immuno‐collagenic subtypes predict response to immune checkpoint blockade
Jie Mei(Sun Yat-sen University), Yongmei Yin(Nanjing Medical University), Yaying Sun(Shanghai First People's Hospital), Yichao Zhu(Nanjing Medical University), Yunlong Yang(Fudan University), Junying Xu(Wuxi People's Hospital), Zhiwen Luo(Fudan University), Zhiwen Qian(Nanjing Maternity and Child Health Care Hospital), Ying Jiang(Jiangnan University), Jiaofeng Zhou(Harbin Medical University), Qing Li(Army Medical University), Di Li(National Engineering Research Center for Nanotechnology), Yan Zhang(Wuhan University), Yuxin Shi(Wuxi People's Hospital), Jiahui Chu(Jiangsu Province Hospital), Rui Xu(Fudan University Shanghai Cancer Center), Jiayu Liu(Weifang Medical University), Shuai Liang(Weifang Medical University), Yun Cai(Jiangsu University)
Cited by 36
Related Papers
Primary results from IMpassion131, a double-blind, placebo-controlled, randomised phase III trial of first-line paclitaxel with or without atezolizumab for unresectable locally advanced/metastatic triple-negative breast cancer
|Annals of Oncology|2021|724
The IFN-γ/PD-L1 axis between T cells and tumor microenvironment: hints for glioma anti-PD-1/PD-L1 therapy
|Journal of Neuroinflammation|2018|268
The PDGF-BB-SOX7 axis-modulated IL-33 in pericytes and stromal cells promotes metastasis through tumour-associated macrophages
|Nature Communications|2016|187
Natural Coevolution of Tumor and Immunoenvironment in Glioblastoma
|Cancer Discovery|2022|137